[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0517268A - método para tratar uma forma de leucemia linfocìtica crÈnica - Google Patents

método para tratar uma forma de leucemia linfocìtica crÈnica

Info

Publication number
BRPI0517268A
BRPI0517268A BRPI0517268-3A BRPI0517268A BRPI0517268A BR PI0517268 A BRPI0517268 A BR PI0517268A BR PI0517268 A BRPI0517268 A BR PI0517268A BR PI0517268 A BRPI0517268 A BR PI0517268A
Authority
BR
Brazil
Prior art keywords
treating
lymphocytic leukemia
chronic lymphocytic
anxamycin
hsp10
Prior art date
Application number
BRPI0517268-3A
Other languages
English (en)
Inventor
Thomas J Kipps
Francis J Burrows
Adeela Kamal
Carlo E Prada
Januario E Castro
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of BRPI0517268A publication Critical patent/BRPI0517268A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

MéTODO PARA TRATAR UMA FORMA DE LEUCEMIA LINFOCìTICA CRÈNICA. Método novo de tratar leucemia linfocitica crónica pela administração de inibidores de HSP9O, particularmente ansamicinas, mais particularmente 1 7-alilamino- 1 7-demetoxigeldanamicina (1 7-AAG).
BRPI0517268-3A 2004-11-02 2005-11-02 método para tratar uma forma de leucemia linfocìtica crÈnica BRPI0517268A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62463804P 2004-11-02 2004-11-02
PCT/US2005/039816 WO2006050457A2 (en) 2004-11-02 2005-11-02 Methods and compositions for treating chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
BRPI0517268A true BRPI0517268A (pt) 2008-10-07

Family

ID=36319809

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517268-3A BRPI0517268A (pt) 2004-11-02 2005-11-02 método para tratar uma forma de leucemia linfocìtica crÈnica

Country Status (13)

Country Link
US (1) US20080280878A1 (pt)
EP (1) EP1814392A4 (pt)
JP (1) JP2008519031A (pt)
KR (1) KR20070085677A (pt)
CN (1) CN101072504A (pt)
AU (1) AU2005302000A1 (pt)
BR (1) BRPI0517268A (pt)
CA (1) CA2584266A1 (pt)
IL (1) IL182618A0 (pt)
MX (1) MX2007004893A (pt)
NO (1) NO20072190L (pt)
RU (1) RU2007120473A (pt)
WO (1) WO2006050457A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050373A2 (en) 2004-11-02 2006-05-11 The Regents Of The University Of California Methods and compositions for modulating apoptosis
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101220068B (zh) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 一组格尔德霉素衍生物及其制备方法
MX2010008269A (es) 2008-02-01 2011-02-21 Takeda Pharmaceutical Inhibidores de hsp90.
CN102216775B (zh) * 2008-08-18 2014-04-16 马克斯·普朗克科学促进协会 对hsp90-抑制剂的易感性
AU2009293218A1 (en) * 2008-09-17 2010-03-25 Charles A. Kallick Treatment for leukemia and idiopathic aplastic anemia
DE102008061214A1 (de) * 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) * 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
CA2440809A1 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050074457A1 (en) * 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
WO2003066005A2 (en) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
US7329502B2 (en) * 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
EP1587519A4 (en) * 2003-01-10 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF CANCER WITH 2-DEOXYGLUCOSE
CA2539548A1 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
PT1716119E (pt) * 2003-12-23 2013-06-04 Infinity Discovery Inc Análogos de ansamicinas contendo benzoquinona para o tratamento do cancro

Also Published As

Publication number Publication date
WO2006050457A2 (en) 2006-05-11
JP2008519031A (ja) 2008-06-05
CN101072504A (zh) 2007-11-14
IL182618A0 (en) 2007-07-24
US20080280878A1 (en) 2008-11-13
CA2584266A1 (en) 2006-05-11
EP1814392A4 (en) 2008-06-11
NO20072190L (no) 2007-07-13
MX2007004893A (es) 2007-06-14
EP1814392A2 (en) 2007-08-08
WO2006050457A3 (en) 2006-12-14
RU2007120473A (ru) 2008-12-10
KR20070085677A (ko) 2007-08-27
AU2005302000A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
CL2009001993A1 (es) Compuestos derivados de 6-oxo-4-fenilamino-1,6-dihidropiridina-3-amida, inhibidores de mek; proceso de preparacion de estos, utiles en el tratamiento de un trastorno hiperproliferativo o una condicion inflamatoria. (divisional de la solicitud cl 1168-06)
AR110313A2 (es) Derivados de tiazol-2-il-pirrolidina
TW200700362A (en) Process for producing an organic compound
CR9866A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicoticos y neurodegenerativos
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
HK1088597A1 (en) Method for the production of substituted 3-aryl-butyl amine compounds
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200500239A1 (ru) Новый способ синтеза (1s)-4-,5-диметокси-1-(метиламинометил)-бензоциклобутана и его солей присоединения и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
NO20060403L (no) Kjemiske forbindelser
MY145788A (en) Antitumoral dihydropyran-2-one compounds
TN2009000151A1 (en) Mapk/erk kinase inhibitors
UY30185A1 (es) Método para la producción preferencial de isómeros geométricos y método de aislamiento
BRPI0517268A (pt) método para tratar uma forma de leucemia linfocìtica crÈnica
NO20061302L (no) Derivater av hydroksaminsyre som metalloproteinseinbitorer
MX2014000437A (es) Composicion para el control de plagas artropodas y metodo para controlarlas.
PL1845780T3 (pl) Zastosowanie pochodnych metylofenidatu
EA200500202A1 (ru) Новый способ синтеза (7-метокси-3,4-дигидро-1-нафталинил)ацетонитрила и его применение при синтезе агомелатина
MX274842B (es) Procedimiento para la produccion de sales de (4,5-dihidroisoxazol- 3-il)tiocarboxamidina.
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
DE60323748D1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produfür deren herstellung
MY142220A (en) Labelled inorganic additives
TW200621756A (en) Method for manufacturing enantiomeric imidazole compounds
ITMI20060488A1 (it) Procedimento per la preparazione di 3,4-bis trifluoronetil-n-metilbenzilammina
NO20053208D0 (no) Metode for reduktiv dehalogenering.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.